Core Insights - Silver experienced a remarkable rally, surging 137% from February 2025 to February 2026, with the iShares Silver Trust (SLV) climbing from $29.46 to $69.72 [1] - The volatility in January 2026, triggered by speculation regarding the Federal Reserve chair, led to a 17.5% selloff, testing investor conviction [1] - The current market sentiment around silver remains bullish, with retail investors showing signs of recovery after the January shakeout [1] Silver Price Action - Silver's 137% gain over the past year significantly outpaces its 176% return over the previous five years, compressing a typical five-year performance into just twelve months [1] - The metal briefly touched $95 before reversing during the January volatility, indicating extreme price fluctuations [1] - Year-to-date, SLV is up 8.2%, reflecting ongoing volatility beneath the surface [1] ETF Flows and Investor Sentiment - The iShares Silver Trust holds $51.5 billion in net assets with a 0.5% expense ratio, indicating strong investor interest [1] - Sentiment on Reddit fluctuated during the January crash, with posts highlighting both significant losses and gains from SLV put options [1] - By mid-February, sentiment had rebounded to a bullish range of 64-68, suggesting a repositioning among retail investors [1] Silver Miners Performance - Silver mining stocks have amplified gains, with First Majestic Silver (AG) returning 304%, Hecla Mining (HL) at 256%, and Coeur Mining (CDE) at 211% [1] - The valuations of these mining companies have expanded significantly, with First Majestic trading at 164x trailing earnings and Pan American Silver (PAAS) at 33x [1] Drivers of Silver Demand - Industrial demand for silver remains robust, driven by sectors such as solar panel production, AI infrastructure, and electronics manufacturing [1] - Central bank gold buying indirectly supports silver prices through the gold-to-silver ratio, highlighting the interconnectedness of precious metals [1] - Key factors to watch include the sustainability of industrial demand, miners' production management, and the behavior of retail investors post-January [1]

Summit Therapeutics (NASDAQ:SMMT) is one of the 17 biotechnology stocks with more than 50% upside. As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) was moderately bullish. The stock had received coverage from 6 analysts, 4 of whom had assigned Buy ratings and 2 gave Hold calls. With no Sell rating, the stock carries a projected median 1-year price target of $57.98, implying a strong upside of more than 296%. Adaptive Biotechnologies (ADPT) Hits 3-Year H ...

Centessa Pharmaceuticals (NASDAQ:CNTA) is one of the 17 biotechnology stocks with more than 50% upside. On January 29, Danielle Brill from Truist Financial raised her price target on Centessa Pharmaceuticals (NASDAQ:CNTA) from $33 to $38 and assigned a Buy rating to the stock. Her rating came after Truist Financial updated its projections following a thorough reassessment of the current data regarding the orexin-2 receptor agonist class. Zoetis (ZTS) Hits New 52-Week Low on Dismal Outlook M. A. Arkhipov ...

Group 1 - Spyre Therapeutics (NASDAQ:SYRE) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a projected median 1-year price target of $57.86, indicating an upside of over 66% [1] - The company has received coverage from 7 analysts, all of whom have assigned Buy ratings, reflecting a strongly bullish consensus sentiment [1] - As of January 22, 2026, Spyre Therapeutics plans to prioritize six proof-of-concept (POC) readouts, with the SKYLINE ulcerative colitis trial completing SPY001 enrollment ahead of schedule, and the SKYWAY basket trial on track for fourth-quarter readouts in 2026 [2] Group 2 - Financially, Spyre Therapeutics reported $783 million in pro forma cash, cash equivalents, and marketable securities as of September 30, 2025, providing a runway through the second half of 2028 [2] - The company is a clinical-stage biotechnology firm focused on developing advanced antibody therapeutics for inflammatory bowel disease (IBD), including conditions such as ulcerative colitis and Crohn's disease [3] - Spyre's current pipeline includes multiple candidates: SPY001, SPY002, SPY003, and various combination therapies [3]

Vera Therapeutics (NASDAQ:VERA) is one of the 17 biotechnology stocks with more than 50% upside. On January 27, Anupam Rama of JPMorgan maintained an Overweight rating on Vera Therapeutics (NASDAQ:VERA) with a $96 price target. His estimates imply upside of more than 127%. Liquidia Corporation (LQDA) Gains Momentum Following Overturning of District Court Patent Ruling Copyright: dolgachov / 123RF Stock Photo Rama believes the shares offer strong upside potential from the current trading range. He antic ...

Company Overview - Arcellx Incorporated (NASDAQ:ACLX) is focused on developing advanced immunotherapies for cancer patients and other incurable conditions, utilizing proprietary D-Domain technology to create effective treatments targeting AML, multiple myeloma, and other malignancies [3]. Analyst Ratings - Rothschild & Co Redburn analyst Qize Ding downgraded Arcellx's rating from Buy to Neutral, reducing the price target from $113 to $82, indicating a revised upside potential of nearly 20% [1]. - Stifel analyst Stephen Willey reaffirmed a Buy rating with a price target of $127, suggesting an upside potential of 85% from the current level [2]. Clinical Data and Competitive Position - Willey's positive outlook followed the presentation of new laboratory study data at the TANDEM meeting, which indicated that anito-cel has a potentially leading safety profile with lower unintended immune activity and fewer off-target effects compared to rival CAR-T treatments [3]. - The data suggests that anito-cel may be positioned as a best-in-class therapy, differentiating it from cilta-cel (Carvykti) and ide-cel (Abecma) due to its reduced off-target interactions linked to severe delayed side effects [3]. Pipeline Development - The current pipeline includes the development of ACLX-001 and ACLX-002, targeting BCMA in relapsed/refractory multiple myeloma (rrMM) and CD123 in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) [3].

Core Insights - Apogee Therapeutics (NASDAQ:APGE) is identified as one of the 17 biotechnology stocks with more than 50% upside potential, with a current price target of $95 set by Citi analyst Geoff Meacham, indicating a potential upside of over 37% [1] - RBC Capital analyst Brian Abrahams downgraded Apogee Therapeutics from Outperform to Sector Perform, while raising the price target from $70 to $83, suggesting nearly 20% upside [2] - The market reaction to the release of Sanofi's Phase 3 amlitelimab data is viewed as an overreaction, with Meacham asserting that it does not negatively impact the prospects for Apogee's APG279 candidate [1] Company Overview - Apogee Therapeutics is a clinical-stage biotechnology company focused on developing novel biologics for treating inflammatory and immune diseases, including atopic dermatitis, asthma, chronic obstructive pulmonary disease, and eosinophilic esophagitis [4] - The company's pipeline includes several candidates at different clinical trial stages, such as APG777, APG279, APG990, APG333, and APG808 [4] Market Context - The segment in which Apogee operates is becoming increasingly competitive, with established players posing challenges despite the potential of its primary drug, zumilokibart, as a long-acting IL-13 treatment for atopic dermatitis [3] - The share price of Apogee has surged by 108% over the past year, which may limit the potential for further gains [3]

来源：环球市场播报 作者：杰克・康利 上周市场的核心主题是 AI 引发的震荡。由于市场担忧 AI 对业务的颠覆性冲击，软件、房地产、金融 服务、物流等板块股票普遍遭遇抛售。 上周五，以科技股为主的纳斯达克综合指数（^IXIC）下跌 0.2%，全周累计下跌 2.1%。 该数据发布前，上周公布的 1 月消费者价格指数（CPI）显示，通胀放缓幅度超预期。 周五，投资者还将看到密歇根大学消费者信心指数，这是衡量消费者情绪与实际支出数据是否匹配的关 键指标。本月早些时候，该指标升至去年 8 月以来新高，但仍低于去年同期水平。 企业方面，市场焦点大概率落在周四沃尔玛（WMT）四季度财报上。沃尔玛是消费支出的重要风向 标，本次财报也是新任 CEO 约翰・弗纳首次亮相财报发布。 其他值得关注的财报包括： 周三的 DoorDash（DASH）、摩森康胜（TAP）；以及一批将反映AI 用电需求如何改变能源行业的公 司：星座能源（CEG）、能源传输（ET）、南方电力（SO）均将发布业绩。 美国市场周一因总统日休市。 标普 500 指数（^GSPC）周五小幅上涨不足 0.1%，但全周仍下跌 1.4%。道琼斯工业平均指数（^DJI） ...

Key Takeaways VRSK is set to report Q4 results on Feb. 18, with revenues anticipated to rise 4.9% y/y.Verisk expects growth from Reimagine pricing, subscription gains and AI-led claims support.VRSK's EPS is projected at $1.58, indicating a 1.9% fall on higher depreciation, interest and taxes.Verisk (VRSK) is scheduled to release fourth-quarter fiscal 2025 results on Feb. 18, before market open.VRSK surpassed the Zacks Consensus Estimate for earnings in the trailing four quarters, delivering an average surpr ...

The Bank of New York Mellon Corporation (NYSE:BK) is one of the 10 Best Bank Stocks to Buy in 2026. JPMorgan raised its target price on BNY Mellon by 2.8% to $128.50 (from $125.00), while reiterating the firm’s Overweight call on the stock. This TP update comes as the firm updated its financial models for large-cap banks, following the release of Q4 2025 earnings. In its other bank TP updates, the firm noted that it prefers the banking sector for this market cycle. BNY Mellon released its Q4 2025 on Jan ...